At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses the development of management strategies for patients with follicular lymphoma. In the relapsed setting, promising novel therapeutic agents include the phosphoinositide 3-kinase inhibitors, idelalisib and duvelisib; the immunomodulatory agent, lenalidomide; the anti-CD20 monoclonal antibody, obinutuzumab; the Bcl-2 inhibitor, venetoclax; and antibody-drug conjugates. In the frontline setting, promising novel therapeutic approaches include a combination of lenalidomide and the anti-CD20 monoclonal antibody, rituximab.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates